Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers for preeclampsia

A biomarker, preeclampsia technology, applied in the field of biomarkers, can solve problems such as increased HbF concentration

Inactive Publication Date: 2017-12-01
A1M PHARMA
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This overproduction and leakage of HbF leads to increased concentration of HbF in maternal plasma and further induces ROS and inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for preeclampsia
  • Biomarkers for preeclampsia
  • Biomarkers for preeclampsia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0244] Discussion of results

[0245] In the study, the inventors used PE as a model disease to investigate the response of the cell-free Hb defense network in pathological conditions with prolonged hemolytic elevation. Therefore, to investigate the physiological relevance and possible pathophysiological importance of acellular HbF in the disease progression of PE, we investigated acellular HbF (both free, expressed as HbF, and complexed with Hp, expressed as Hp-HbF) on the main human endogenous Hb clearance system: Hp, Hpx, A1M and CD163. This allowed us to study the potential of HbF, Hp-HbF, Hb-total, A1M, Hp, Hpx and CD163 as biochemical markers to support the diagnosis of PE.

[0246] In this study, we characterized acellular HbF and endogenous Hb- and heme clearance systems in pregnant women diagnosed with PE at term and in normal pregnancies (controls). Consistent with previous results, we found a significant increase in HbF in women with PE 11 . In addition, plasma ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-microglobulin as markers for preeclampsia.

Description

technical field [0001] The present invention relates to biomarkers for preeclampsia, early onset preeclampsia (before 34 weeks of pregnancy) and late onset preeclampsia. In addition, biomarkers that predict maternal and fetal outcome in women with preeclampsia were identified. Biomarkers were i) hemopexin (Hpx), Hpx bound to α1-microglobulin (A1M), or iii) HpX bound to A1M and free circulating fetal hemoglobin (free HbF). The panel of markers can be supplemented with a group selected from haptoglobin-fetal hemoglobin complex (Hp-HbF), haptoglobin (Hp), heme oxygenase-1 (heme oxygenase-1) ( HO-1) and other markers of heme. CD163 and CD163 binding to Hpx may be markers of fetal outcome. Both Hpx levels and activity (the latter representing Hpx-a) can be used. Background technique [0002] Preeclampsia (PE) makes all pregnancies 1 Complicates in 3-8% and manifests clinically in the second half of pregnancy. The clinical features that define PE are the onset of hypertensio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/689G01N2333/4713G01N2333/805G01N2800/368C12Q2600/158G01N2800/50
Inventor 斯特凡·汉斯布·阿克斯特罗姆芒努斯·约兰·格拉姆
Owner A1M PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com